Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Nivestim® in Patients Treated With Neutropenia-inducing Anticancer Chemotherapy in Routine Practice

NCT01574235 is registered in ClinicalTrials.gov with Hospira, now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT01574235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01574235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Nivestim® in Patients Treated With Neutropenia-inducing Anticancer Chemotherapy in Routine Practice
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Phase
Observational
Overall status
Completed
Start date
October 31, 2011
Completion date
February 28, 2014
Enrollment
2,114 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced febrile neutropenia (fn), malignant hemopathy, solid tumors